Representative Matters
REFERENZMANDATE
代表事项
M&A and Strategic Partnerships
- Valo Health in its announced 2021 business combination with Khosla Ventures Acquisition Co. ($2.8 billion)
- Cerevel Therapeutics in its 2021 business combination with ARYA Sciences Acquisition Corp II ($440 million)
- Represented financial advisor in Pandion Therapeutics’ 2021 definitive sale to Merck ($1.85 billion)
- KIND in its 2020 definitive acquisition by Mars, Incorporated ($5 billion)
- MyoKardia in its 2020 acquisition by Bristol Myers Squibb ($13.1 billion)
- Represented financial advisor in Immunomedics’ 2020 sale to Gilead Sciences, Inc. ($20 billion)
- Represented financial advisor in Principia Biopharma’s 2020 acquisition by Sanofi ($3.68 billion)
- Represented financial advisor in Forty Seven’s 2020 acquisition by Gilead Sciences ($4.9 billion)
- AMAG Pharmaceuticals in its 2020 sale to Covis Group ($500 million)
- Represented financial advisor in Arqule’s 2020 acquisition by Merck ($2.7 billion)
- Spark Therapeutics in its 2019 sale to Roche ($4.4 billion)
- Twilio in its 2019 acquisition of SendGrid ($3 billion)
- Civitas in its 2019 acquisition by Centerbridge ($1.4 billion)
- Keryx in its 2018 merger with Akebia ($1.3 billion)
- Foundation Medicine in its 2015 majority sale to Roche ($1 billion) and the subsequent 2018 negotiated tender for the public stub by Roche ($2.4 billion)
- PTC in its 2018 strategic partnership with Rockwell Automation ($1 billion)
- PAREXEL in its 2017 sale to Pamplona ($5 billion)
- AMRI in its 2017 sale to Carlyle and GTCR ($1.9 billion)
- The 2016 Reverse Morris Trust merger of a division of Citrix into LogMeIn ($2 billion)
- The 2016 private company sale of Stemcentrix to Abbvie ($5.8 billion)
- Teva Pharmaceuticals in its 2015 acquisition of Auspex ($3.5 billion)
- Xoom in its 2015 sale to PayPal ($1 billion)
- Onyx Pharmaceuticals in its 2013 sale to Amgen ($10.4 billion)
- Eloqua in its 2012 sale to Oracle ($1 billion)
Financings and Public Offerings
- Moderna in connection with its
- 2020 follow-on public offerings ($500 million in March and $1.34 billion in May)
- 2018 record biotech initial public offering ($604 million)
- 2018 private financing ($500 million)
- 2016 private financing ($474 million)
- Cerevel Therapeutics in its 2021 underwritten public offering ($350 million)
- Repertoire Immune Medicines in its 2021 Series B financing ($189 million)
- Aura Biosciences in its 2021 private financing ($80 million)
- Rubius Therapeutics in connection with its
- 2021 underwritten public offering ($200 million)
- 2018 initial public offering ($277.3 million)
- 2018 crossover financing ($100 million)
- 2017 private financing ($120 million)
- Valo Health in its 2021 Series B ($300 million)
- Tessera Therapeutics in its 2021 Series B financing ($230 million)
- Represented the underwriters of Trivago’s 2016 initial public offering ($330 million)
Special Committee Representations
Mr. Cable is also retained from time to time to represent "independent" or "special" committees of the Board of Directors in complex M&A transactions, including most recently the representation of the Special Committee of the Board of Directors of NantKwest in NantKwest’s merger with ImmunityBio (March 2021) and the Transaction Committee of Sprint in Sprint Corporation’s merger with T-Mobile US, Inc. (April 2020).
COMMUNITY AND PRO BONO ACTIVITIES
Mr. Cable serves as a member of the President's Leadership Council at Dartmouth College, as chairman emeritus of the Buckingham Browne & Nichols School and as a member of the Board of the Arthur L. Irving Institute for Energy & Society at Dartmouth College. He also served for more than a decade as a member of the Board of Fellows of Harvard Medical School.
Mr. Cable leads the firm’s pro bono efforts on behalf of Camp Harbor View, a summer enrichment program for Boston’s youth founded by Jack Connors. Mr. Cable is also a member of the Goodwin pro bono team advising the Boston Red Sox Foundation on Board and governance matters.
